TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase ® Technologies Inc. (" Theralase ® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF )( FRA:TTX ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has... Read More

TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses, has been granted a Canadian patent for a new cancer... Read More

TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's audited annual consolidated... Read More

TORONTO, ON / ACCESSWIRE / March 26, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDCs ") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that it is hosting... Read More

TORONTO, ON / ACCESSWIRE / February 12, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses, donated two Theralase® TLC-2400 Cool Laser Therapy... Read More

TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses is pleased to announce that Dr. Michael Jewett has... Read More

TORONTO, ON / ACCESSWIRE / February 5, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed... Read More

TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses is providing an update regarding its Phase II... Read More

TORONTO, ON / ACCESSWIRE / November 29th, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective... Read More

TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has has successfully... Read More

TORONTO, ON / ACCESSWIRE / November 17, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") used for the safe and effective destruction of various cancers, bacteria and viruses, has commenced a non-brokered private placement... Read More

TORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses. Theralase® is pleased to announce that it has entered... Read More

Post Study II Monitoring of Response, Optional Maintenance Study II Treatments and Central Pathology Laboratory Review Optimized TORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for... Read More

Theralase®'s Latest Clinical Data Demonstrates 65% of Patients Treated with Theralase®'s Anti-Cancer Therapy Achieved a Complete Response TORONTO, ON / ACCESSWIRE / October 16, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ) is a clinical-stage pharmaceutical company... Read More

Theralase®'s Latest Preclinical Data Supports Combining Immunotherapy Drugs with Theralase® PDCs for Increased Cancer Destruction TORONTO, ON / ACCESSWIRE / October 5, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the... Read More

TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds (" PDCs "), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and... Read More

TORONTO, ON / ACCESSWIRE / September 27, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activatedPhoto Dynamic Compounds (" PDCs "), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively... Read More

TORONTO, ON / ACCESSWIRE / September 21, 2023 / Theralase ® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDCs "), their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers, announces... Read More

TORONTO, ON / ACCESSWIRE / September 7, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), is a clinical stage pharmaceutical company focused on the research, development and commercialization of light activated Photo Dynamic Compounds (" PDCs "), their associated drug formulations and the light systems that activate them, to destroy various cancers, bacteria and viruses,... Read More

TORONTO, ON / ACCESSWIRE / August 29, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDCs "), their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers has released the... Read More

TORONTO, ON / ACCESSWIRE / June 30, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDCs ") and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that it has... Read More

TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (" PDCs ") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment... Read More

In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release. TORONTO, ON / ACCESSWIRE / May 30, 2023 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDCs... Read More

TORONTO, ON / ACCESSWIRE / May 30 2023 / Theralase® Technologies Inc. (" Theralase " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDCs ") and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company's 1Q2023 unaudited condensed... Read More

TORONTO, ON / ACCESSWIRE / May 24, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (" PDCs ") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce that Roger... Read More

For the primary objective, 65% of Evaluable Patients (Patients evaluated by a Principal Investigator ("PI")) achieved a Complete Response ("CR") at any assessment date post primary Study Treatment and 30% of Evaluable Patients achieved a CR at 450 days. TORONTO, ON / ACCESSWIRE / May 10, 2023 / Theralase ® Technologies Inc. (" Theralase ® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical... Read More

TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated drug formulations intended to... Read More

TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that its Phase II... Read More

TORONTO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce it has been... Read More

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“ Theralase® ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that its Phase II... Read More

TORONTO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“ Theralase® ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that its Phase II... Read More

TORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Theralase ® Technologies Inc. (“ Theralase ” or “ Company ”) ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date... Read More